EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance

Junyan Li, Liyuan Zhang, Yan Shang, Juan Liu, Hailong Zhao

Clinical and Translational Medicine · 2026-01 · 16 (1)

DOI: 10.1002/ctm2.70586 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 15.01.2026. Verfasst von Junyan Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Zunyi Medical University, Zunyi, Guizhou, China. Hauptthemen laut MEDLINE: Neoplasms, Synthetic Lethal Mutations, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 266 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China Regional Project, Guizhou Province Science and Technology Plan Project, National College Students Innovation and Entrepreneurship Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Rationale Synthetic lethality (SL)‐based strategies hold significant promise for overcoming therapeutic resistance, a critical bottleneck in cancer treatment where cancer cells evade anticancer therapies, leading to diminished efficacy or treatment failure. The core of SL lies in exploiting tumour‐specific vulnerabilities: drug‐resistant cells often acquire unique genetic defects or compensatory adaptive responses, and SL strategies selectively target genes or pathways dependent on these vulnerabilities to induce specific cell death, thereby reversing resistance. Content and Focus This review systematically elaborates on SL mechanisms and the multi‐faceted nature of tumour drug resistance, then focuses on how SL counteracts resistant phenotypes by leveraging resistant cells’ vulnerabilities. We further delineate SL applications in preclinical resistance models, highlight representative SL‐related drugs and predictive biomarkers and critically analyse challenges in clinical translation. Conclusion By integrating mechanistic insights, preclinical validation and translational perspectives, this review aims to provide novel insights for precision therapy and a foundational reference to advance SL strategies in overcoming tumour resistance and facilitating their clinical implementation. Key points SL‐based strategies exploit tumour‐specific vulnerabilities in drug‐resistant cells to induce selective cell death and overcome therapeutic resistance. This review dissects SL mechanisms, diverse drivers of tumour drug resistance and how SL counteracts resistant phenotypes via these vulnerabilities. It summarises clinical translational applications of SL from preclinical studies to trials, approvals and emerging targets, and discusses future precision therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsSynthetic Lethal MutationsDrug Resistance, NeoplasmHumansAnimalsTranslational Research, BiomedicalAntineoplastic Agents

Stichwörter der Autor:innen

DNA damage response reprogrammingcancer therapeutic resistanceclinical translationgenome‐scale CRISPR screeningsynthetic lethality

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Genetics, Zunyi Medical University, Zunyi, Guizhou, China.
  • Key Laboratory of Cell Engineering of Guizhou Province, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
  • Guizhou Biomanufacturing Laboratory, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
  • Department of Pathophysiology, Zunyi Medical University, Zunyi, China.

Förderung

  • National Natural Science Foundation of China Regional Project
  • Guizhou Province Science and Technology Plan Project
  • National College Students Innovation and Entrepreneurship Training Program
  • Guizhou Provincial Basic Research Program(Natural Science)
  • Collaborative Research Fund Project of Zunyi Bureau of Science and Technology
  • Science and Technology Research Fund of Guizhou Health Commission

Zitieren

APA

Li, J., Zhang, L., Shang, Y., Liu, J., & Zhao, H. (2026). Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance. Clinical and Translational Medicine, 16(1). https://doi.org/10.1002/ctm2.70586

Vancouver

Li J, Zhang L, Shang Y, Liu J, Zhao H. Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance. Clinical and Translational Medicine. 2026;16(1). doi:10.1002/ctm2.70586

BibTeX
@article{Li2026,
  author = {Li, Junyan and Zhang, Liyuan and Shang, Yan and Liu, Juan and Zhao, Hailong},
  title = {Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  volume = {16},
  number = {1},
  doi = {10.1002/ctm2.70586}
}
Kostenlos starten →